Furagin-SZ, tablets 50 mg, 30 pcs.

Furagin is an antibacterial drug, a nitrofuran derivative. It acts bacteriostatically. The mechanism of action of Furagin is associated with the effect on the enzymes involved in the transfer of hydrogen in the cells of sensitive microorganisms.

The high bacteriostatic activity of Furagin is due to the presence of aromatic nitro group.

The drug is active against Gram-positive bacteria: Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus faecalis; Gram-negative bacteria: Enterobacteriaceae, Escherichia coli, Klebsiella pneumoniae.
Pseudomonas aeruginosa is resistant to the drug.

The minimum bacteriostatic concentration of Furagin (1 µg/ml) is 10-20 times lower than that of other nitrofuran derivatives. Furagin has the most pronounced effect in acidic environment (pH 5.5), alkaline environment prevents the action of the drug.

Indications

– treatment of acute and chronic infectious and inflammatory diseases of the urinary tract and prostate;
– prevention of recurrent urinary tract infections (including in children with congenital defects of the urinary system, in adults with prolonged catheterization).

Active ingredient

Composition

1 tablet contains:

the active ingredient:

furazidine 50 mg

How to take, the dosage

In adults the drug is prescribed in the first day of therapy in the dose of 100 mg (2 tablets) 4 times a day, on subsequent days – 100 mg 3 times a day.
In children the drug is prescribed in a daily dose of 5-7 mg/kg of body weight, in long-term treatment – in a daily dose of 1-2 mg/kg.

The course of treatment is 7-8 days. If necessary the course of treatment can be repeated after 10-15 days.

To prevent the drug, 50 mg (1 tablet) 1 time per day (preferably in the evening).

The tablets should be taken with food containing proteins.

Interaction

In concomitant use of Furagin and nalidixic acid there is a decrease in the bacteriostatic effect of Furagin.

Concomitant use of Furagin and uricosuric drugs (probenecid, sulfinpyrazone) decreases excretion of furazidine in the urine, which leads to a decrease in its therapeutic effectiveness. This may lead to cumulation of furazidine in the body and increase the toxicity of Furagin.

Concomitant use of Furagin and antacids containing magnesium trisilicate decreases absorption of Furagin.

Special Instructions

Care should be taken when prescribing Furagin to patients with diabetes mellitus because symptoms of polyneuropathy may appear against the background of using the drug.

Furagin is not recommended in case of urosepsis as well as in case of infections of the renal parenchyma.

When using Furagin, false positive results of glucose determination in urine using Benedict and Fehling solutions may be observed. Results of urine glucose determination performed by enzymatic methods remain correct.

Control of laboratory parameters

During long-term treatment with Furagin, the leukocyte count in blood as well as indicators of liver and kidney function should be periodically monitored.

Impact on driving and operating machinery

Furagin does not affect the speed of psychomotor reactions, therefore it can be administered to patients whose activities require increased attention.

Contraindications

– renal insufficiency;
– polyneuropathy (including. Diabetic);
– Insufficiency of glucose-6-phosphate dehydrogenase;
– Pregnancy: between 38 and 42 weeks;
– Lactation;
– Hypersensitivity to nitrofuran derivatives.
The drug is not prescribed to newborns before the end of the first month of life.

Side effects

Digestive system: diarrhea, dyspeptic symptoms, abdominal pain, constipation, vomiting.
CNS and peripheral nervous system: dizziness, drowsiness, visual disturbances; rarely – polyneuropathy.
Allergic reactions: rash, itching.
Other: fever, chills, malaise; rarely – pulmonary reactions caused by hypersensitivity to nitrofuran derivatives.

Overdose

Symptoms: headache, dizziness, depression, psychosis, peripheral polyneuritis, allergic reactions (urticaria, angioedema, bronchospasm), nausea, vomiting, megaloblastic or hemolytic anemia (in persons with glucose-6-phosphate dehydrogenase deficiency); very rarely – liver dysfunction.

The treatment: gastric lavage, intravenous infusion of infusion solutions; hemodialysis is indicated in severe cases.

Similarities